Last reviewed · How we verify
Zactima
At a glance
| Generic name | Zactima |
|---|---|
| Also known as | Caprelsa, ZD6474, Vandetanib |
| Sponsor | Barbara Ann Karmanos Cancer Institute |
| Target | AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
- Carcinoma of thyroid
- Medullary thyroid carcinoma
Common side effects
Key clinical trials
- A Phase I, Open Label Study to Assess the Safety and Tolerability of ZD6474 (ZACTIMA) in Combination With Vinorelbine (Navelbine) or Gemcitabine (Gemzar) Plus Cisplatin as First Line Therapy in Patien (Phase 1)
- Randomized Phase 2 Trial of Anastrozole Combined With Novel Agent ZD6474 in the Neoadjuvant Treatment of Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer (Phase 2)
- A Phase II, Open Label Study of ZD6474 in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) (Phase 2)
- A Randomised, Double-blind, Parallel Group, Multi-centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD6474(Vandetanib) 300 mg, BSC Plus ZD6474(Vandetanib) 100 mg (Phase 2)
- A Randomized,Double-blind,Parallel-group,Multicentre,Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/Daily or Placebo)With Fulvestran (Phase 2)
- A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects (Phase 3)
- A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With A (Phase 2)
- A Phase I Study of ZD6474 (Zactima) Alone and in Combination With Retinoic Acid in Relapsed and Refractory Pediatric Neuroblastoma (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zactima CI brief — competitive landscape report
- Zactima updates RSS · CI watch RSS
- Barbara Ann Karmanos Cancer Institute portfolio CI